FDA yet to start evaluating Sinopharm's EUA

The FDA has not yet started evaluating Sinopharm’s application for emergency use authorization (EUA) of its COVID-19 vaccine.

Sinopharm submitted a letter of intent and phase 1 clinical trial results, but the FDA is requesting additional documents such as Phase 3 trial results and certification of good manufacturing practices before beginning the evaluation process.

President Duterte will wait for the FDA’s decision on Sinopharm's EUA before getting vaccinated.